Skip to main content
HR 1734 118th Congress House Science, Technology, Communications Advanced technology and technological innovations Chemistry Congressional oversight Drug trafficking and controlled substances Higher education Research administration and funding Science and engineering education

TRANQ Research Act of 2023

Introduced: March 23, 2023 Introduced by: Collins, Mike Republican · Georgia See on congress.gov
 Everywhere this bill has been 27 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 19, 2023
Became Public Law No: 118-23.
Dec 19, 2023
Signed by President.
Dec 14, 2023
Presented to President.
Dec 4, 2023
Motion to reconsider laid on the table Agreed to without objection.
Dec 4, 2023
On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)
Dec 4, 2023
Resolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)
Dec 4, 2023
DEBATE - The House proceeded with forty minutes of debate on the motion to suspend the rules and agree to the Senate amendment to H.R. 1734.
Dec 4, 2023
Mr. Lucas moved that the House suspend the rules and agree to the Senate amendment. (consideration: CR H6087-6089)
Jun 26, 2023
Message on Senate action sent to the House.
Jun 22, 2023
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S2250-2251)
Jun 22, 2023
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S2250-2251)
Jun 22, 2023
Measure laid before Senate by unanimous consent. (consideration: CR S2250)
May 15, 2023
Received in the Senate, read twice.
May 11, 2023
Motion to reconsider laid on the table Agreed to without objection.
May 11, 2023
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 425 - 0 (Roll no. 212). (text: 5/9/2023 CR H2149)
May 11, 2023
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 425 - 0 (Roll no. 212). (text: 5/9/2023 CR H2149)
May 11, 2023
Considered as unfinished business. (consideration: CR H2295-2296)
May 9, 2023
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
May 9, 2023
DEBATE - The House proceeded with forty minutes of debate on H.R. 1734.
May 9, 2023
Considered under suspension of the rules. (consideration: CR H2149-2151)
May 9, 2023
Mr. Miller (OH) moved to suspend the rules and pass the bill, as amended.
May 5, 2023
Placed on the Union Calendar, Calendar No. 34.
May 5, 2023
Reported (Amended) by the Committee on Science, Space, and Technology. H. Rept. 118-50.
Mar 29, 2023
Ordered to be Reported (Amended) by the Yeas and Nays: 36 - 0.
Mar 29, 2023
Committee Consideration and Mark-up Session Held.
Mar 23, 2023
Referred to the House Committee on Science, Space, and Technology.
Mar 23, 2023
Introduced in House
 Votes taken on this bill 1
DateChamberWhat was voted onResultYes–No
May 11, 2023 House · vote #212 On Motion to Suspend the Rules and Pass, as Amended Passed 4250 See who voted →
 Plain-English summary Congressional Research Service

Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023 or the TRANQ Research Act of 2023

This bill requires the National Institute of Standards and Technology (NIST) to support research and other activities related to identifying xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer), novel synthetic opioids, and other new psychoactive substances.

In particular, NIST must support

  • basic measurement science and research;
  • near-real time spectrometry capabilities (i.e., a technique for rapidly identifying the chemical composition of a substance);
  • strategies and voluntary best practices for handling, transporting, and analyzing such substances; and
  • collaboration with other government agencies, institutions of higher education, and the private sector to enhance relevant narcotic and opioid detection and analysis capabilities.

Additionally, the Government Accountability Office must conduct a study on the capabilities of the federal government to detect, identify, and otherwise respond to threats of new psychoactive substances, such as xylazine.

What's happening now December 19, 2023

Became Public Law No: 118-23.

 Committees of jurisdiction 1